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Abstract: Obesity is a major risk factor for type 2 diabetes mellitus (T2DM), which is a 
  significant health problem worldwide. Active disease is associated with low-grade chronic 
inflammation resulting in part from the activation of the innate immune system. In obesity, this 
activation leads to the release of pro-inflammatory cytokines such as tumor necrosis factor-α, 
interleukin-1β and interleukin-6 that block major anabolic cascades downstream of insulin 
signaling and thus disrupt insulin homeostasis and action. Cytokines also trigger the produc-
tion of acute-phase reactants such as C-reactive protein, plasminogen activator inhibitor-1, 
serum amyloid-A, and haptoglobin. The elevated synthesis of pro-inflammatory cytokines and 
acute-phase proteins (inflammatory network) characterizes the early (or pre-clinical) stages 
of T2DM and exhibits a graded increase with the disease progression. Current evidence sug-
gests that understanding inflammatory networks can point to new biomarkers that may permit 
capturing the interaction between genetic and environmental risk factors in the pathogenesis of 
T2DM. Such biomarkers have a significant public health potential in the prediction of disease 
occurrence beyond risk factors presently monitored, such as family history, lifestyle assessment 
and standard clinical chemistry profiles. Furthermore, inflammatory markers may assist in the 
evaluation of novel strategies for prevention, particularly in relation to micronutrients. This 
review discusses the current knowledge linking T2DM risk to inflammatory signaling pathways 
interacting with the innate immunity system and the prospect of inflammatory markers serving 
as molecular targets for prevention and/or biomarkers for early risk prediction of T2DM. The 
potential of micronutrients replenishment to improve insulin action by attenuating inflammation 
is also evaluated in the context of the public health relevance of this approach.
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Introduction
Type 2 diabetes mellitus (T2DM) represents a significant global health problem. It 
is estimated that six people die every minute from the disease worldwide, a figure 
that will soon make T2DM one of the world’s most prevalent causes of preventable 
mortality.1 The incidence of disease increases with age, obesity, physical inactivity, 
unhealthy diet, and ethnicity (Hispanics, Africans, and Aboriginals) and the rates are 
increasing among children.2,3 T2DM is caused by impaired glucose tolerance (IGT) 
as a result of insulin resistance and consequential islet β-cell exhaustion, with ensuing 
insulin deficiency impacting skeletal muscle, liver and adipose tissues.4 In individuals 
with IGT, numerous genetic, host-related, and environmental factors contribute to 
the progression of insulin resistance to T2DM.5–9 Obesity, however, is a major cause 
of insulin resistance7 and can be complicated by metabolic dysregulation including Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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hypertension and dyslipidemia (known collectively as the 
metabolic syndrome) which is a precursor of T2DM. The 
dyslipidemia involves high levels of triacylglycerides and 
circulating fatty acids originating from the diet or acceler-
ated lipolysis in adipocytes. Direct exposure of muscle cells 
to these fatty acids impairs insulin-mediated glucose uptake 
and, therefore, may contribute to insulin resistance.10,11
Within the last decade, a hypothesis was proposed to 
explain the pathogenesis of T2DM that connects the disease 
to a state of subclinical chronic inflammation.12,13 Inflamma-
tion is a short-term adaptive response of the body elicited as 
a principle component of tissue repair to deal with injuries 
and microbial infections (eg, cold, flu, etc.). It can be also 
elevated in chronic conditions such as peripheral neuropathy, 
chronic kidney disease and fatty liver. While the influence of 
fats is well known (see below), current thinking suggests that 
abnormal levels of chemokines released by the expanding 
adipose tissue in obesity activate monocytes and increase the 
secretion of pro-inflammatory adipokines. Such cytokines in 
turn enhance insulin resistance in adipose and other tissues, 
thereby increasing the risk for T2DM.14,15 Together, lipid tox-
icity and low-grade inflammation appear to be major assaults 
on insulin sensitivity in insulin-responding tissues.11,16,17
Activation of innate immunity promotes various inflam-
matory reactions that provide the first line of defense the 
body invokes against microbial, chemical, and physical 
injury, leading to repair of damage, isolation of microbial 
infectious threats and restoration of tissue homeostasis.18,19 
Inherited variations in the degree of innate immune response 
may determine the lifetime risk of diseases upon exposure to 
adverse environmental stimuli.20 Therefore, innate immune 
responses can be viewed as the outcome of interaction 
between genetic endowment and the environment.21 The 
systemic reaction of innate immunity, known as the ‘acute-
phase response’, follows exposure to an exogenous insult 
(such as a pathogen or dietary factor) which triggers the 
release of pro-inflammatory cytokines like tumor necro-
sis factor (TNF)-α, interleukin (IL)-1β and IL-6.22 These 
cytokines are derived primarily from macrophages and can 
directly enhance insulin resistance in adipocytes, muscle and 
liver cells.11,17 Macrophages infiltrate the expanding adipose 
tissue in obesity to remove dying cells and contribute to tis-
sue angiogenesis.23 The adipose tissue of obese rodents and 
humans is indeed excessively infiltrated by macrophages 
and dendritic cells.11 Subsequent activation of macrophages 
towards an inflammatory phenotype results in cytokine syn-
thesis and release.24,25 Cytokines then downregulate major 
anabolic cascades involved in insulin signaling and mediate 
adipocyte insulin resistance.24,25 Ultimately, this contributes 
to disruption of whole-body insulin sensitivity and impairs 
glucose homeostasis.26
In addition to their effect on insulin resistance, cytokines 
also act on the liver to increase the production of very-low 
density lipoproteins (VLDL), leading to the characteristic dia-
betic dyslipidemia,27 and to stimulate the hepatic production 
of fibrinogen, an atherosclerotic risk factor.12 Furthermore, 
cytokines deactivate the liver X receptors (LXR), resulting in 
an increased rate of cholesterol accumulation,28 and ultimately 
trigger the hepatic production and secretion of acute-phase 
proteins such as C-reactive protein (CRP), plasminogen 
activator inhibitor-1 (PAI-1), serum amyloid-A, α1-acid 
glycoprotein, and haptoglobin (collectively known as inflam-
matory factors or markers) into the circulation. The synthe-
sis of acute-phase reactants following the cytokine release 
characterizes the pre-clinical (or early) stages of T2DM21 
and exhibits graded increases as the disease progresses and 
clinical complications ensue12 (see below).
Extensive experimental, clinical and epidemiological 
studies have linked obesity causally to the activation of 
inflammatory signaling pathways and to the subsequent 
manifestations of T2DM.7,29,30 This relationship may facili-
tate the development of preventive measures for the disease 
at the early stages, as well as its main antecedent, obesity. 
For example, pharmaceutical and nutritional factors that 
reduce inflammation and the ensuing acute-phase reactant 
responses could be employed to improve insulin sensitivity 
and delay disease onset.31–33 Furthermore, a subset of the 
pro-inflammatory cytokines and inflammatory factors may 
provide a phenotypic profile that can be utilized as a sensi-
tive and specific composite biomarker for early detection of 
risk to T2DM. Taken together, these approaches may aid 
in reducing the rising rates of disease incidence and better 
address issues related to prevention and treatment.
This review was undertaken to examine current knowl-
edge linking inflammatory signaling pathways within the 
innate immune system to the risk of T2DM. The possibility 
that inflammatory markers could serve as molecular targets 
for prevention and/or biomarkers for early risk prediction of 
T2DM is evaluated in the context of enhancing public health 
strategies for diabetes prevention and control.
Obesity, T2DM, and inflammation: 
Molecular mechanism(s) of 
association
In obese people, insulin resistance is linked to the increased 
release of adipocyte-derived bioactive metabolites (ADBMs) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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such as lipids, free fatty acids, monocyte chemoattractant 
  protein-1 (MCP-1), and pro-inflammatory cytokines.30 It 
should be emphasized, however, that although obesity is 
viewed as a predisposing factor to insulin resistance, other fac-
tors may also contribute. A study of young, insulin-resistant, 
lean offspring of patients with T2DM and insulin-sensitive 
controls of similar body mass index (BMI) showed similar 
plasma concentrations of TNF-α, IL-6, and adiponectin 
between the insulin-resistant and insulin-sensitive groups.34 
This suggests that in lean people, systemic inflammation 
may not play a significant role in the development of insulin 
resistance. In this case, proposed mechanisms for insulin 
resistance might then be attributed to a dysregulation of intra-
myocellular fatty acid metabolism.14 In the liver this would 
also include an altered expression of transcription factor 6-α 
(ATF6) which controls expression of gluconeogenic genes.35 
Genetic predisposition also may contribute to the development 
of T2DM. Genome-wide association (GWA) and candidate 
gene studies over the past few years have so far uncovered 19 
genes associated with T2DM.36 The disease-related genetic 
variants identified have high frequencies in the populations 
assessed although their individual contributions to increases 
in risk of T2DM are modest. Ongoing GWAs that target low-
frequency genetic variants and assess copy number variants 
(CNVs) in addition to single nucleotide polymorphisms 
(SNPs) are likely to identify additional loci associated with 
T2DM risk, and some of these may play a significant role 
in the risk of disease development.36 In lean subjects with 
T2DM, the dysregulation of fatty acid metabolism, the 
abnormal expression of gluconeogenic genes and the genetic 
predisposition necessitate the development of an additional 
set of biomarkers that target this subpopulation and relate to 
these risk factors.
In the obesity-related insulin resistance, once adipo-
cytes are activated (ie, accumulate fat and exhibit caloric 
excess), they release abnormal levels of ADBMs, leading 
to the recruitment of monocytes within adipose tissues.30 
Monocyte differentiation into the macrophages lineage 
results in additional increases in the release of inflamma-
tory factors and chemokines, propagating inflammatory 
responses both locally within adipose tissue and systemi-
cally elsewhere.14,17,30 In both human37 and animal16 models,   
TNF-α gene expression is upregulated in adipose tissues 
during obesity, linking pro-inflammatory substances released 
from adipose tissues to insulin resistance in T2DM.
The role for pro-inflammatory cytokines in regulating 
insulin action and glucose homeostasis and their function 
in T2DM has been suggested by several lines of evidence. 
For example, compared to healthy individuals, subjects with 
T2DM risk factors such as obesity, hyper-triglyceridemia, 
or low high-density lipoprotein (HDL)-cholesterol exhibit 
higher serum levels of pro-inflammatory cytokines and 
acute-phase reactants than those who are not so predisposed.13   
Cytokines also show a gradual increase as the disease 
progresses to its complications.13 Additionally, numerous 
prospective trials demonstrate that initial high levels of 
pro-inflammatory factors are associated with the manifesta-
tions of the disease.38–43 Baseline circulating concentrations 
of IL-6, PAI-1, CRP, and fibrinogen were significantly 
higher in healthy subjects who became diabetic later in life 
(ie, after 4–10 years) compared to those who did not develop 
the disease.38–43 Furthermore, exogenous administration of 
TNF-α or IL-6 results in insulin resistance,16,17,37 whereas 
low serum levels of cytokine in knock-out mice17,44 or treat-
ment with anti-TNF-α agents,31 improved insulin sensitivity 
and glucose homeostasis. However, TNF-α is unlikely to be 
the only culprit for inducing insulin resistance and indeed 
many cytokines may act in synchrony to elicit the condition. 
Taken together, these observations suggest that inflammation 
is a feature when IGT develops at the pre-clinical stages of 
T2DM, perhaps at the overweight or obesity (see below).
The mechanisms that govern the association between 
the increased synthesis of inflammatory factors and T2DM 
are still being elucidated. In macrophages, adipocytes, 
antigen-presenting B-cells, dendritic cells, and Kupffer 
cells in the liver, a number of germline-encoded pattern 
recognition receptors (PRRs), such as the toll-like receptors 
(TLR), are activated upon ligand binding with conserved 
structural motifs that are either specific patterns of micro-
bial components (eg, bacterial lipopolysaccharide [LPS])45 
or nutritional factors (eg, free fatty acids [FFAs]).11,18,46–48 
Binding to PRRs gives rise to inflammatory responses by 
mediating downstream transcriptional events that activate 
nuclear factor-κB (NFκB) and activator protein-1 (AP-1) 
and their pathways (see Figure 1).19 Upon activation, these 
intracytoplasmic molecular cascades upregulate the transcrip-
tion of pro-inflammatory cytokine genes22 and, consequently, 
the synthesis of acute-phase inflammatory mediators49–51 and 
activation of c-Jun N-terminal kinase (JNK) and inhibitor 
of NFκB kinase-β (IKK). In liver and adipose tissue, these 
two molecules can inactivate the first target of the insulin 
receptor (INSR), IRS-1, thereby reducing downstream sig-
naling towards metabolic outcomes.52,53 The interrelationship 
between these molecular targets suggests the expression 
and action of PRRs are the primary effector molecules 
in a downstream cascade that initiate dysregulation of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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insulin homeostasis. Therefore, altered expression/action, eg, 
as a result of SNP, in these PRRs may be employed to predict 
the possible development of T2DM (or earlier predisposing 
conditions) upon exposure to high levels of their ligands.
In addition to the activation of inflammation signals, 
strong evidence supports a direct role of FFAs in promoting 
insulin resistance. This has been ascribed to actions of their 
intracellular metabolites, primarily ceramide and diacylg-
lycerol, on proteins that impinge on insulin-derived signals. 
Mixtures of FFAs arterially injected in vivo induced the 
activation of protein kinase C (PKC)-Θ or JNK in skeletal 
muscle.11,17,52 PKC-Θ, like JNK, can inactivate IRS-1 and its 
downstream signaling towards metabolic outcomes.52 This 
is achieved by distinct serine phosphorylation of IRS-1 that 
reduces the signal-bearing tyrosine phosphorylation.29 In 
contrast, saturated FFAs act largely to produce ceramides 
that spare IRS-1 but still inhibit insulin action downstream, 
at the level of the serine/threonine kinase Akt to also inhibit 
metabolic outcomes.54,55 Interestingly, direct exposure of 
insulin-target cells to cytokines such as TNF-α and IL-1β 
also activates JNK and IKK,56 making these factors a com-
mon link in the molecular mechanism of lipotoxicity and 
inflammation leading to insulin resistance and T2DM via 
post-transcriptional actions.53 Indeed, heterozygous deletion 
in IKKβ (ie, in IKKβ+/- mice) improved insulin sensitivity 
in obese mice target cells.57 In addition, TNF-α upregulates 
the expression of suppressor of cytokine signaling (SOCS) 
proteins, which bind to IRS-1 to mediate its degradation.58 
Furthermore, cytokine-mediated transcriptional up-regulation 
of JNK and IKK increases the expression of AP-1 and NFκB59 
that, in turn, activate TNF-α to further propagate local and 
systemic inflammatory responses.60 Hence, JNK–AP-1 and 
IKK–NFκB are the major inflammatory pathways that disrupt 
insulin signaling via a series of transcriptional events and can 
be potentially modulated to improve insulin sensitivity and 
glucose homeostasis.17
Figure 1 The interaction between insulin signaling and fatty acids in the synthesis of pro-inflammatory cytokines and inflammatory markers.
Notes: Current information suggests that insulin activates INSR to stimulate the phosphorylation of multiple tyrosine residues in the IRS and promote diverse biological 
responses. Illustrated here is the response of stimulation of glucose transport into muscle and fat cells. Activation of TLR4 by fatty acids initiates intracytoplasmic signals 
that activate the JNK–AP-1 and IKK–NFκB axes which in turn increase the expression of cytokine-encoding genes. Cytokines initiate the hepatic production of APPs (eg, 
CRP, fibrinogen, haptoglobin, etc.) and dysregulate the INSR-IRS-mediated glucose transport into promoting serine phosphorylation of IRS that in turn reduces its tyrosine 
phosphorylation and, thereby, disrupts the insulin action.
Abbreviations: AKT, protein kinases B (PKB); AP-1, activator protein-1; APPs, acute phase proteins; G, glucose; GLUT4, glucose tansporter-4; I, insulin; IKK, inhibitor of 
NFκB kinase-β; IL-1β and -6, interleukin-1 β and -6; INSR, insulin receptor; IRAK1 and 4, interleukin-1 receptor-associated kinase 1 and 4; IRS, insulin substrate; JNK, c-Jun 
amino-terminal kinase; MyD88, myeloid differentiation primary response gene-88; NFκB, nuclear factor κ B; PI3K, phosphoinositide-3 kinase. PI(3,4,5)P3, Phosphatidylinositol 
3,4,5-trisphosphate. PKC, protein kinase C. TAB, TAK binding protein. TAK1, mitogen-activated protein kinase kinase kinase (MAPKKK). TLR4, toll-like receptor-4; TNFα, tumor 
necrosis factor-α; TRAF6, TNF receptor-associated factor 6.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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An additional and highly relevant interaction between 
lipids and inflammation is the recent discovery that FFAs 
can directly activate macrophages to produce cytokines that 
render muscle cells insulin resistant.11,61 Such studies in cell 
culture are proof of principle that elevated FFAs can activate 
cells of the innate immune system to provoke muscle cell 
insulin resistance. In this case, both the macrophages and 
muscle cells showed activated JNK and IKK.
Inflammatory network: Biomarkers 
of  T2DM
It is estimated that up to 25% of patients with newly diag-
nosed T2DM already present evidence of systemic inflam-
mation at the time of diagnosis,62 suggesting that the disease 
(or the hypertriglyceridemia) has been present already for 
years since the development of status that predisposes to 
the disease (eg, overweight; see Figure 2).63–65 Current 
approaches to diabetes screening include determination 
of an elevated fasting plasma glucose level (126 mg/dL,   
ie, 7.0 mmol/L) on two occasions, or an oral glucose tolerance 
test (OGTT) yielding 200 mg/dL (11.1 mmol/L) after 2 h, 
or symptoms of uncontrolled diabetes with a random plasma 
glucose level 200 mg/dL (11.1 mmol/L). In addition, a score 
of glycosylated hemoglobin levels above 7% (HbA1c  0.07) 
has been suggested as evidence of disease.4 None of these 
techniques has been found to detect all incident cases of 
T2DM and there is still a need to establish more sensitive 
and specific predictors of early risk.66 Although inherited 
dysfunction in insulin signaling plays a role in the risk of 
T2DM, it is likely that any genetic component will be modi-
fied by environmental factors. Capturing the contribution of 
these genetic factors and their interaction with environmental 
covariates (eg, diet, physical activity, etc.) in the development 
of T2DM may provide an effective approaches for early 
detection and prevention.66,67
Inherited variations such as SNPs or CNVs in genes 
encoding for innate immunity-related inflammation may 
play a pivotal role in the susceptibility to T2DM and an 
array of chronic diseases.68–72 Genetic polymorphisms, in 
conjunction with various environmental factors, may affect 
serum levels of cytokines and inflammatory markers and 
the subsequent risk of T2DM68–71 (see Table 1). Identifica-
tion of SNPs or CNVs of inflammation-related genes, their 
frequencies and their association with risk of T2DM will 
assist in defining the genetic basis of the disease and early 
detection of risk.
Resistin
FFA
TNFα
Adiponectin
PREVENTION
Overweight Obesity
Insulin resistance
Cardiovascular disease
Metabolic
syndrome T2DM
CRP
Fibrinogen
IL-6
Haptoglobin
IL-1β
TG
Hypertension
LDL
HDL
IGT
Figure 2 The relationship of inflammatory markers and disease factors to specific stages pathologic continuum from overweight to T2DM and cardiovascular diseases.63,64
Note: Depicted are the increases or decreases (see text) in relative values of various inflammatory markers and disease factors that take place as overweight progresses 
towards T2DM.
Abbreviations: CrP, C-reactive protein; FFA, free fatty acids; IGT, impaired glucose tolerance; IL, interleukin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
TG, triglycerides; T2DM, type 2 diabetes mellitus.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
178
Badawi et al
The feasibility of utilizing inflammatory markers in 
screening T2DM risk can be substantiated from numerous 
experimental, clinical and epidemiological observations 
  demonstrating: a) the ability of inflammatory factors to 
predict the disease independently from established risk 
  factors,73–76 b) their link to one another by virtue of their 
common action, and c) the availability of quantitative, less-
invasive methods of assay, that would allow for repeated 
measurements. These characteristics render inflammatory 
mediators as potential candidates for a panel of powerful 
biomarkers for predicting T2DM incidence. As indicated 
in Figure 2, overweight sets the stage for low-grade chronic 
inflammation, with adiponectin levels decreasing while 
resistin, FFAs and TNF-α increase. As overweight progresses 
to obesity, continued inflammation further leads to elevated 
CRP, fibrinogen, IL-6, IL-1β and haptoglobin. Obesity can 
be complicated by metabolic dysregulation (metabolic syn-
drome) to develop frank T2DM where LDL-cholesterol and 
triglyceride levels increase, HDL-cholesterol levels deceases 
and hypertension and IGT manifest.9,29,30,65,66,77 Throughout 
the pathologic continuum from overweight to T2DM, insulin 
resistance increases progressively and the risk of cardiovas-
cular disease (CVD) elevates. Metabolic syndrome is asso-
ciated with about twofold increased susceptibility to CVD 
whereas T2DM is linked to fourfold higher risk.63,64 Public 
health initiatives aimed at preventing and controlling T2DM 
should be targeted towards the early stages of the disease, to 
prevent obesity and the cascade of inflammatory events that 
eventually leads to the clinical manifestation of T2DM. We 
next discuss the characteristics of cytokines and chemokines 
with potential to become biomarkers of inflammation and 
insulin resistance associated with obesity, ie, early T2DM 
risk detection.
TNF-α
TNF-α is a primary mediator of many of the systemic 
acute responses related to severe infections with gram-
negative bacteria.78 The major cellular source of TNF-α 
is activated mononuclear phagocytes, antigen-stimulated   
T-cells, natural killer (NK) cells, and mast cells. The TNF-α 
gene is constitutively expressed in adipose tissue, where it 
originates principally from macrophage infiltration rather 
than from the adipocytes themselves.16 In adipose tissue 
from obese subjects, TNF-α mRNA expression is 2.5-fold 
higher than in lean subjects and is strongly correlated with 
hyperinsulinemia.26 Body weight reduction in obese people26 
and in vivo TNF-α inhibition16 significantly reduced serum 
TNF-α and improved insulin sensitivity. High TNF-α is 
related to the pathophysiology of insulin resistance and 
T2DM,45 possibly through its impact on IRS-1 as discussed 
above,16,26,58,79 or by enhancing the apoptosis of pancreatic 
β-cells.80
The association of the TNF-α gene polymorphisms with 
T2DM has been extensively investigated but with conflict-
ing results. Some studies demonstrate a strong association 
between TNF-α SNPs and T2DM81–83 (Table 1) whereas 
others show no relationship.84,85 Although a number of vari-
ants have been identified in the TNF-α gene, the functional 
SNPs rs361525 (-238 GA) and rs1800629 (-308 GA) 
were identified in the promoter region. The functionality of 
the variant -308A allele is related to a twofold increase in 
transcriptional activity compared to the wild-type allele.86 
Interestingly, this variant was suggested to play a critical 
role in the genetic predisposition to excessive fat accumula-
tion in women in early stages of obesity,82 and to predict the 
conversion from IGT to T2DM.81 The rs1800629 SNP exhib-
ited a gene–gene interaction effect with the IL-6 rs1800795 
(-174 CG) in the early risk prediction of T2DM.81 On the 
other hand, the rs361525 is located in a repressor site of the 
promoter, a 10 bp sequence with homology to the binding 
site of the activator protein AP-2 regulating TNF-α func-
tion.87 Another SNP in TNF-α which was recently reported 
to be associated with increased risk of T2DM, is rs1800610 
(IVS1+123 GA).83 The functional relevance of this SNP 
pertains to the YY1 transcription factor that binds specifically 
to the intron 1 region where the rs1800610 resides and evokes 
increased TNF-α expression.83
iL-6
IL-6 is produced by many cell types including fibroblasts, 
endothelial cells, and monocytes-macrophages.88,89 However, 
a significant proportion of the circulating IL-6 (15%–30%) 
Table 1 Selected pro-inflammatory cytokine gene polymorphisms 
positively associated with  T2DM and related risk factors and clinical 
complications68–72a
Conditionb SNP
BMi iL-6 -174CG, iL6 CA rep., TNFα -308GA
iGT iL-6 -174CG
insulin resistance iL-6 -174CG, TNFα -308GA
Obesity iL-6 -174CG, iL6r 394TG, TNFα -308GA
T2DM iL-6 -174CG, iL6r 48867AG, TNFα  
-308GA, TNFα -863CA
Diabetic nephropathy iL-6 -634CG, iL1β -511CT
Note:  aA selected list of SNPs positively linked to T2DM and related conditions 
was presented.
Abbreviations: BMi, body mass index; iGT, impaired glucose tolerance; iL, interleukin. 
rep., repeats; TNFα, tumor necrosis factor-α; T2DM, type 2 diabetes mellitus.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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derives from adipose tissue production in the absence of 
acute inflammation90 to modulate adipocyte glucose and 
lipid metabolism.91,92 In obesity, IL-6 synthesis is upregulated 
in adipocytes88,93 and correlates with circulating IL-694 and 
with the extent of insulin resistance.77,93,95 IL-6 also triggers 
the hepatic synthesis of CRP and correlates with its serum 
  levels.94,95 Additionally, IL-6 promotes hepatic VLDL secre-
tion and hypertriglyceridemia.27,96 These observations suggest 
a link between IL-6 levels, obesity and inflammation in the 
pathogenesis of T2DM97 and demonstrate that IL-6 can be 
considered as a candidate biomarker for early T2DM risk 
detection.
Several mechanisms have been proposed to explain how 
IL-6 can mediate insulin resistance.17,56,77,93,95,98 The IL-6 
receptor (IL6R) belongs to the cytokine class I receptor 
family that includes the JNK signal transduction pathway.53,99 
JNK activation by IL-6 induces STAT (signal transducers 
and activators of transcription) phosphorylation, dimeriza-
tion, and translocation to the nucleus to regulate the tran-
scription and function of an array of target genes including 
IRS, AP-1, and NFκB53,59 in hepatocytes and adipocytes.100 
Transcriptional upregulation of these genes promotes both 
localized and systemic inflammatory responses60 to mediate 
fatty liver and insulin resistance.101 The interaction between 
IL-6 and the insulin pathway also involves mediating the 
interaction between SOCS proteins and the INSR.102–104 
Therefore, IL-6 antagonists and factors that target JNK and 
IKK may offer promising preventive and/or therapeutic 
approaches to improve insulin sensitivity.32,105
In humans, numerous studies have demonstrated that 
elevated levels of IL-6 are associated with an increased 
incidence of T2DM independent of obesity73–76 or fasting 
insulin levels.74 The relative risk of the disease for individu-
als with IL-6 levels in the highest tertile (vs lowest tertile) 
was 2.02 (95% confidence interval [CI]: 1.14–3.58), after 
adjustment for BMI, lifestyle factors, and pre-existing 
CVD.73 Furthermore, chronically elevated IL-6 was related 
to a range of metabolic abnormalities typical of an insulin 
resistant state.97 Several polymorphisms exist in the IL-6 and 
IL6R (Table 1). Two common SNPs in the promoter region of   
IL-6, rs1800795 (-174 GC) and rs1800796 (-572 GC) 
were examined for their role in predisposition to T2DM. 
These SNPs were investigated in a large meta-analysis 
of 20,000 participants from 21 published and unpublished 
studies for their association with T2DM.106 The allele -174C 
was associated with reducing the risk of T2DM by nearly 
10% (odds ratio [OR] = 0.91; P  0.037) and exhibited 
a gene–gene interaction with the TNF-α rs1800629 in 
predicting disease risk.81 No evidence for association was 
found, however, between rs1800796 and T2DM.106 Overall, 
these findings, although indicative of a role for IL-6 poly-
morphisms in T2DM, suggest that additional studies are 
needed to confirm this association, particularly in relation 
to other genes along the innate immunity and inflammatory 
pathways. Moreover, studies that examine gene–environment 
interactions may yield more meaningful results and provide 
important insights into the role of IL-6 in the pathogenesis 
of T2DM as well as its value as a biomarker of early disease 
risk detection.
CrP
CRP is an acute-phase reactant produced primarily in the 
liver under the stimulation of adipocyte-derived IL-6 and 
TNF-α. It exhibits several characteristics that imply a fun-
damental immunoregulatory function. Specifically, CRP is 
a member of the pentraxin family of oligomeric proteins 
involved in PRRs activation. CRP also enhances leukocyte 
reactivity, complement fixation, modulation of platelet acti-
vation, and clearance of cellular debris from sites of active 
  inflammation.50,107 The magnitude and rapidity of its induc-
tion and its cooperative role in innate immune response, as 
well as its ease of measurement, all make CRP a common 
marker for inflammation.108 Furthermore, CRP is invariably 
correlated with various parameters relevant to diabetes, 
including obesity, lipogenesis, and adiponectin.66 In this 
respect, CRP was shown to be consistently associated with 
the incidence of T2DM in populations of otherwise healthy 
persons.66,109 A recent study estimated that one-third of T2DM 
cases can be associated with elevated serum CRP.109 Although 
the relationship between CRP and T2DM was thought to be 
stronger in women than men,42 subjects of both sexes with 
high serum CRP (2.6 mg/L) had more than double the 
overall T2DM risk (OR = 2.37; 95% CI: 1.57–3.58) com-
pared to those with levels of 0.5 mg/L.109 Together, these 
findings substantiate a role for CRP as a possible candidate 
biomarker for early T2DM risk detection.
Numerous prospective studies demonstrate an inde-
pendent positive association of CRP with the presence of 
T2DM38,75,76,109–114 while others show no association after 
adjustment for adiposity and insulin resistance.39,41,74,115 
A meta-analysis of available data from 10 prospective stud-
ies showed a positive association between serum CRP and 
T2DM independent of obesity.109 Another meta-analysis of 
16 published studies with 3,920 T2DM cases and 24,914 con-
trols demonstrated a relative risk (RR) of T2DM of 1.72 (95% 
CI: 1.54–1.92) for subjects with high CRP levels.116 A major Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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mechanism by which CRP plays a critical role in T2DM is 
primarily by its action on pancreatic β-cell.117,118 For example, 
CRP significantly inhibits cell proliferation and increases the 
rates of apoptotic cell death.119 This effect was connected to the 
CRP-mediated modulation of protein kinase B (PKB), a key 
factor for cell survival pathways and to its ability to induce the 
production of TNF-α, IL-1β and matrix metalloproteinase-9 
(MMP-9) in a concentration-dependent manner.119
Several SNPs were identified in the CRP gene and 
were linked to elevated levels of serum CRP,120 low insulin 
sensitivity,121 and incidence of T2DM.122–124 Among these 
SNPs, the variants rs3093059 (2757 AG)120,121,123 and 
rs2794521 (2717 AG)120–123 were extensively studied and 
were reported to be associated with an increased risk of 
T2DM. Furthermore, CRP SNPs at the 3 end–rs1800947 
(1059 GC) and rs1130864 (1444 CT)–were associ-
ated with decreased and increased concentrations of CRP, 
respectively.125 Several studies demonstrate that serum CRP 
can be additively influenced by the IL-6–CRP gene–gene 
interaction.126–129 Increased serum CRP in obese individuals 
was correlated with elevated secretion of IL-6 and TNF-α 
in adipocytes and predisposes to the chronic inflammatory 
state associated with T2DM.21
Overall, evaluating the effect of inflammatory factors 
in T2DM may provide new public health approaches for 
disease prevention and a novel strategy for early detection. 
These markers are evidently related to risk of T2DM and can 
be employed in early detection of disease risk and as a predic-
tive measure of response to preventive intervention. If the 
extent of interaction between the genetic (eg, polymorphisms 
in TNF-α, IL-6, and CRP genes), biochemical (eg, serum 
levels of TNF-α, IL-6, and CRP), and environmental (eg, 
micronutrient supplementation) factors and the risk of T2DM 
can be established, a selected set of innate immunity-related 
inflammatory markers could become a powerful panel of 
integrated multiplex biomarkers for the early risk detection 
of T2DM. This integration may permit maximizing the sen-
sitivity, specificity, and predictability of biomarkers to T2DM 
in the general population. A set of inflammatory markers 
could be utilized to develop effective and novel strategies 
for disease intervention based on supplementation with 
micronutrients that modify (ie, lower) their gene expression 
or serum levels (see below).
Attenuating inflammatory response 
in T2DM by micronutrients
Factors that attenuate inflammation (and the inflammatory 
markers proposed above, such as TNFα, IL-6, and CRP) 
could provide an important public health tool to reduce the 
burden of diseases related to this pathway, such as obesity, 
T2DM and cardiovascular diseases, in the general popula-
tion. The feasibility of modulating innate immunity-related 
inflammation as an approach for the prevention of T2DM 
is based on reports that evaluated the efficacy of anti-
  inflammatory pharmaceutical agents on disease manifestation 
and outcome.14,32,105
The major current therapeutic agents to treat T2DM, 
sulfonylureas, metformin, and insulin-sensitizing glitazones, 
all improve metabolic control and lead to normalization of 
circulating inflammation markers through, at least partly, 
interaction with the innate immunity-related pathway. Sul-
fonylureas increase insulin release from pancreatic β-cells,130 
whereas metformin suppresses glucose production in the 
liver and increases insulin sensitivity in peripheral tissues.131 
Glitazones bind to peroxisome proliferator-activated recep-
tors (PPARs), initiating transcriptional activity that leads 
to improved insulin action.132 While not necessarily acting 
primarily to reduce inflammation, it is likely that these drugs’ 
correction of glucose and insulin levels impinges on the 
innate immune system, attenuates inflammation and further 
improves insulin action. Accordingly, glitazones reduced 
serum levels of CRP (30% reduction in 1 week), PAI-1, 
TNF-α and other inflammatory markers.7,133 Statins, metfor-
min and sulfonylureas have comparable anti-inflammatory 
activity.8,9,134
A therapeutic strategy for T2DM that would act primary 
on the inflammatory system has been proposed in the form 
of salicylates, an anti-inflammatory agent that inhibits IKK135 
and is long known to have a hypoglycemic effect.136,137 Non-
steroidal anti-inflammatory drugs (NSAIDs) and cyclooxy-
genase inhibitors are able to enhance glucose-induced insulin 
release, improve glucose tolerance, and increase the effect of 
insulin in patients with T2DM.17,29,105 In humans, treatment 
with NSAIDs improved various biochemical indices asso-
ciated with T2DM (Table 2). Although these observations 
support the notion that inflammation plays a pivotal role in 
T2DM, attenuating inflammation as a strategy for disease 
prevention in a public health setting will necessitate a sub-
stantially different perspective. In this case, a strategy that 
can be introduced into the general population with the least 
(if any) side effects and the maximal preventive outcome 
should be adopted. In this context, a nutritional intervention 
approach would be a desirable option.
In general, studies in animal models and humans have 
demonstrated that disrupting the IKKβ-NFκB pathway 
improves obesity-related insulin sensitivity.14 Furthermore, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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blocking JNK activity in animal models of diabetes enhanced 
systemic glucose homeostasis and insulin sensitivity,32 
whereas inhibition of IKK by salicylates led to an overall 
improved insulin action.105
Micronutrient, certain fatty acids (eg, omega-3 fatty 
acid) and/or trace element supplementation can modify 
innate immune-related responses and, subsequently, modify 
the risk of a range of chronic conditions. With respect to 
T2DM, the consensus of available information suggests that 
micronutrient intake modulates the innate immune system138 
and can subsequently influence the predisposition to (and 
prevention of) disease.80,138,139 By virtue of this observation, 
the hope is that the outcome of nutritional supplementation 
can be simply monitored via its modifying action on the 
levels of inflammatory biomarkers. Many micronutrients 
exhibit well-characterized anti-inflammatory or immuno-
modulatory functions (see below). Vitamins (eg, D, E, and 
C), certain fatty acids (eg, omega-3 fatty acid) and trace 
elements (eg, selenium, zinc, copper and iron) are known 
to improve the overall function of the immune system, 
prevent excessive expression and synthesis of inflammatory 
cytokines, and increase the ‘oxidative burst’ potential of 
macrophages.138 Natural health products (NHPs) that contain 
pertinent micronutrients (eg, so-called adaptogenic medicinal 
plants) or modulate the innate immune system on their own 
(eg, omega-3 fatty acids and probiotics) also represent an 
interesting avenue to study, although the evidence base for 
their beneficial action is highly variable.140 Exploring the 
possibility that supplementation with selected micronutrients, 
trace elements and/or other NHPs can attenuate obesity-
related inflammation in order to delay the development of 
T2DM should be considered alongside existing public health 
  practices to reduce the rising incidence of the disease.
vitamin D
Vitamin D insufficiency has been associated with a wide 
range of chronic diseases, including autoimmune diseases, 
atherosclerosis, cancer, obesity, cardiovascular diseases, and 
diabetes.141 In T2DM, the role of vitamin D was suggested 
from the presence of vitamin D receptors (VDR) in the pan-
creatic β-islet cells.142 In these cells, the biologically active 
metabolite of vitamin D (ie, 1,25-dihydroxy-vitamin D; 
1,25(OH)D)138 enhances insulin production and secretion 
via its action on the VDR.142 Indeed, the presence of vitamin   
D-binding protein (DBP), the principal predictor of 
serum levels of 25(OH)D and response to vitamin D 
  supplementation,143 and VDR initiated several studies 
demonstrating a relationship between SNPs in the genes 
  regulating VDR and DBP with glucose intolerance and insulin 
secretion.144–146 This further supports a role of vitamin D in 
T2DM and may explain the reduced overall risk of T2DM in 
subjects who ingest 800 IU/d of vitamin D.80,139 However, 
an alternative, and perhaps related, explanation was recently 
proposed based on the potent immunomodulatory func-
tions of vitamin D.147–149 VDRs are present in most types of 
immune cells150 and 1,25(OH)D modulates the production of 
the immunostimulatory IL-12 and the immunosuppressive 
IL-10.151 In this respect, supplementation with vitamin D33 
or its bioactive form 1,25(OH)D138 improved insulin sensi-
tivity by preventing the excessive synthesis of inflamma-
tory cytokines. This effect on cytokine synthesis is due to 
its interaction with vitamin D response elements (VDRE) 
present in the promoter region of cytokine-encoding genes. 
This interaction downregulates the transcriptional activities 
of cytokine genes and attenuates the synthesis of the corre-
sponding proteins.33 Vitamin D also deactivates NFκB that 
transcriptionally regulates the pro-inflammatory cytokine-
encoding genes.152 Downregulating the expression of NFκB 
and downstream cytokine genes inhibits β-cell apoptosis 
and promotes their survival.33 Numerous intervention trials, 
clinical studies, and epidemiological findings demonstrated 
that supplementation with vitamin D can be beneficial in opti-
mizing processes linked to T2DM such as insulin response,   
and hence, may markedly improve T2DM prevention strat-
egies.80,142 For example, increasing intake of vitamin D 
to 800 IU daily, along with 1200 mg of calcium, reduced 
the risk of developing T2DM by 33%.80 In agreement, healthy 
older adults with impaired fasting glucose showed significant 
improvement in glycemic and insulin responses when they 
Table 2 Effect of attenuating inflammation by anti-inflammatory 
factors on biochemical measures of predisposition to T2DM105a
Characteristic Effectb % Changec
Fasting plasma glucose ↓ 25
Basel hepatic glucose production ↓ 20
Glucose uptake ↑ 20
insulin-stimulated peripheral glucose uptake ↑ 20
insulin clearance ↓ 30
Total cholesterol ↓ 15
Fatty acid levels ↓ 50
Triglycerides ↓ 50
CrP ↓ 15
Notes:  aSubjects with T2DM (n = 9) were treated with high-dose aspirin 
(∼7 g/day divided in 5 equal doses) for two weeks; beffect is shown as decrease (↓) 
or increase (↑); cChanges represent the difference in biochemical measures (%) before 
and after treatment.
Abbreviations: CrP, C-reactive protein; T2DM, type 2 diabetes mellitus.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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increased their intake of vitamin D by 700 IU/day and calcium 
by 500 mg/day for three years.139 Therefore, exploring the 
possibility that vitamin D can modify the action of innate 
immunity genes to attenuate the T2DM-associated low-
grade chronic inflammatory response, and prevent disease 
development and/or progression, may represent an attractive 
approach for public health intervention, both in the general 
population as well as in vulnerable subpopulations. It should 
however, be considered that vitamin D serum levels, and sub-
sequently extent of supplementation, will vary considerably 
depending on sunlight exposure; an observation that should 
be taken into account when employing it in public health 
  intervention of T2DM.
vitamin e
Vitamin E is known to have a significant impact on improv-
ing a variety of immune functions.153 Supplementation with 
vitamin E increases the rate of lymphocyte proliferation 
by enhancing the ability of T cells to undergo cell division 
cycles.154 The effective anti-inflammatory action of vitamin 
E was substantiated from observations such as the increased 
expression of the IL-2 gene and IL-1 receptor antagonist 
and the decreased expression of IL-4 following vitamin E 
supplementation in animal models.153 Furthermore, vitamin 
E reduced the serum levels of IL-1β, IL-6, TNF-α, PAI-1, 
and CRP in T2DM patients.155 These anti-inflammatory 
actions are thought to result from its inhibitory effect on the 
5-lipoxygenase (5-LOX) at the post-transcriptional level.156 
5-LOX is a member of the lipoxygenase family of enzymes 
involved in the synthesis of the inflammatory prostaglandins. 
Additional anti-inflammatory functions of vitamin E include 
its downregulation of NFκB155 and its potent lipophilic anti-
oxidant effect on internal and external cell membranes as 
well as plasma lipoproteins, notably LDL. Based on this latter 
characteristic, studies in both animal models and humans 
have demonstrated that vitamin E intake blocks LDL lipid 
peroxidation, prevents the oxidative stress linked to T2DM-
associated abnormal metabolic patterns (hyperglycemia, 
  dyslipidemia, and elevated levels of FFAs), and, subsequently, 
attenuates cytokine gene expression.153,155,157,158 Despite these 
findings, a recent study evaluated the effects of a combination 
of vitamin C (1000 mg/day) and vitamin E (400 IU/day) for 
four weeks on insulin sensitivity in untrained and trained 
healthy young men and concluded that such supplementation 
may preclude the exercise-induced amelioration of insulin 
resistance in humans.159 This may relate to the source of 
vitamin E used, ie, α-, β- γ-, or δ-tocopherol.160 Neverthe-
less, in general, the immunomodulatory, anti-inflammatory 
and anti-oxidative functions of vitamin E strongly support its 
possible application in designing effective prevention and/or 
treatment protocols for T2DM.157
Current practices for diabetes prevention in the general 
population include lifestyle change, dietary intervention and 
exercise. As suggested above, micronutrient supplementa-
tion may aid in T2DM prevention and control through the 
anti-oxidant, anti-inflammatory and immunomodulatory 
properties of various vitamins and trace elements. It seems 
reasonable, therefore, to suggest that the two preventive 
approaches for T2DM (ie, micronutrient supplementation and 
lifestyle change) may be combined into a single program to 
enhance the success and effectiveness of intervention. This 
strategy could be more efficient in reducing the low-grade 
inflammation associated with pre-clinical T2DM and, sub-
sequently the disease burden, than when a single approach is 
considered. Moreover, such a combined strategy can be intro-
duced in general practice settings and in a population-based 
fashion with low expenditure and minimal side effects.
Conclusions
The current state of knowledge warrants further study into 
the extent of association between inflammatory markers 
and early stages of T2DM, on one hand, and the effect of 
micronutrients in modifying this relationship, on the other. 
Such an approach is critical to comprehensively evaluate the 
prospect of applying inflammatory network assessment in 
disease surveillance. A significant public health potential of 
developing this set of evidence-based biomarkers can be con-
ceptualized from their application as precise genomic-based 
measures of risk prediction for T2DM beyond the simple risk 
factors presently employed, such as family history or physical 
examination. In this respect, inflammatory biomarkers may 
permit capturing the etiological function of (and interaction 
between) genetic constitution and environmental risk modi-
fiers in the T2DM pathogenesis. Furthermore, a major benefit 
of introducing inflammatory markers into public health 
settings stems from their potential to facilitate developing a 
novel class of agents which attenuate low-grade inflammation 
prior to the clinical onset of T2DM and to be employed in 
disease prevention. However, before applying these biomark-
ers in public health, protocols for their assessment should be 
standardized and laboratory reference intervals need to be 
used in decision-making processes.
Employing this set of biomarkers in evaluating responses 
to prevention may necessitate examining the contribution of 
dynamic interaction between genetic and dietary modifiers 
in the etiology of T2DM, as well as the influence of these Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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factors on inflammation at the early disease stages. It seems 
likely that micronutrient supplementation can modify the 
genotype–phenotype association within the innate immune 
response. This proposition may elucidate the mechanisms by 
which nutritional factors prevent or delay disease develop-
ment and can be introduced into the general population and 
susceptible subpopulations. The efficacy of micronutrient 
supplementation to attenuate or balance the innate immune 
response and the ensuing inflammation first needs to be 
further explored and optimized; in some cases, this includes 
developing tools to accurately and reproducibly measure the 
circulating/tissue levels of potential biomarkers in order to 
relate it to clinical outcome. The impact of micronutrients on 
T2DM incidence may then be assessed through a series of 
pilot population-based studies: firstly, to determine the fea-
sibility and effectiveness of this protocol; second, to validate 
and evaluate the strategy and ensure replication of results; 
and, third, to monitor the outcome to quantify the overall 
preventive response in comparison (and combination) with 
the current preventive approaches for T2DM such as lifestyle 
changes, exercise, and dietary intervention.
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